← Leaderboards
Matija Snuderl
New York University
$1,936,042
Attributed
$3,872,083
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $742.6K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,872,083 · 3
By mechanism
R01$2,801,562 · 1
R21$609,584 · 1
R56$460,937 · 1
Top collaborators
- Praveen B. Raju5 shared
- Weiqiang Chen3 shared
Most similar at New York University
Same institution · by research overlap
- Weiqiang Chen$4,205,192
- Paulina Daniela Ramirez Garcia$271,403
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultRadiation TherapyTherapy ResistantTumorMalignant - DescriptorChemotherapyMalignant Neoplasm Of BrainTargeted TreatmentComplexBrain NeoplasmsRegimenDiagnosisDifferential ExpressionBiologyBenignAffectDepositionDissectionAttentional DeficitBrainAreaBrain TissueClinicBlood - Brain Barrier Anatomy
Grant awards (8)
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2$686,834
R01 · FY2025 · NS · contact PI
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2$672,469
R01 · FY2024 · NS · contact PI
Inducing neural maturation in medulloblastoma by targeting EZH2$699,699
R01 · FY2023 · NS · contact PI
Inducing neural maturation in medulloblastoma by targeting EZH2$742,560
R01 · FY2022 · NS · contact PI
Inducing neural maturation in medulloblastoma by targeting EZH2$460,937
R56 · FY2021 · NS · contact PI
Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy$191,878
R21 · FY2020 · EB
Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy$191,760
R21 · FY2019 · EB
Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy$225,946
R21 · FY2018 · EB